David Sinclair· PhD
Very happy to announce our lab’s latest publication on a novel mTORC1 selective rapalog, with great collaborators including @sebuy @BKennedy_aging and Aeonian Pharmaceuticals https://t.co/dTY3XKyKyl #mTOR #rapamycin
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
Very happy to announce our lab’s latest publication on a novel mTORC1 selective rapalog, with great collaborators including @sebuy @BKennedy_aging and Aeonian Pharmaceuticals https://t.co/dTY3XKyKyl #mTOR #rapamycin
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
the lambing group looked at i think it was 90 different wrapalogs presumably related to rapamycin and looked for their ability to be selective for torque 1 even with more sustained exposure then they identified a couple that were and they most of the paper was on one that they liked the best the really cool thing and this is going to get us into an immunofilling discussion is that they found possibly the reason the compound was selective was that it bound to one of the immunofillins but not another so specifically it bound to fkbp at least fkbp12 was required for the compound to have activity but another fkbp fkbp51 was not
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.